Industrial Microbiology Testing Services Market size was over USD 3.56 billion in 2024 and is projected to reach USD 11.18 billion by 2037, witnessing around 9.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of non-invasive respiratory monitoring is assessed at USD 3.82 billion. The reason behind the growth is impelled by the increasing cases of infectious diseases. Clinical microbiology's goal is to definitively diagnose infectious diseases when a clinical infection is suspected and enables the identification of infectious agents based on their unique DNA or RNA sequences by using a variety of testing methodologies including microbiology testing. According to estimates, there were more than 38 million HIV-positive individuals worldwide.
The growing government initiatives to maintain products quality in pharmaceutical and food industry are believed to fuel the market growth. The regulatory system mandates that products meet safety, efficacy, and quality requirements as it maintains a zero-tolerance approach against individuals who undermine the quality of the medications and food. Therefore, the administration reviews the microbiological standards and guidelines for food and makes any necessary amendments to improve food safety.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.2% |
|
Base Year Market Size (2024) |
USD 3.56 billion |
|
Forecast Year Market Size (2037) |
USD 11.18 billion |
|
Regional Scope |
|
Test Type (Sterility Testing, Microbial Limits Testing, Bio-burden Testing, Water Testing, Air Monitoring Tests)
The sterility testing segment in the industrial microbiology testing services market is estimated to gain a robust revenue share of 32% in the coming years owing to the increasing launch of drugs. Successful drug launches have traditionally been a growth driver for pharmaceutical businesses as drug development is being automated using AI and creating opportunities for quicker, less expensive medications.
Sterility testing is a GMP microbiology requirement of pharmaceutical items to guarantee that there are no detectable viable contaminating microorganisms in a product, and verifies that the supplied product is suitably sterile It is necessary for both ordinary release testing and the sterilization validation process so that it can be transmitted for additional use. These tests are essential for maintaining product sterility and ensuring quality control which entails putting a certain amount of a therapeutic product through two filters that are intended to hold microorganisms after that, the filter is rinsed to make sure no medicinal product is left on it as that could stop the growth of microorganisms.
Furthermore, the rules for sterility tests for biological products are being changed by the Food and Drug Administration (FDA) to encourage the use of the most suitable and advanced test procedures for biological product safety assurance. For instance, in 2021, the FDA continued a decade-long trend of increasing medicine approvals by approving more than 45 new medications, and over 53 were authorized by the European Medicines Agency.
Additionally, the microbial limits testing segment is poised to gain a notable share during the forecast timeframe. The microbial limit test (MLT) is used to determine the quantity and type of specific live microorganisms present in non-sterile industrial samples from pharmaceutical goods to evaluate whether or not a product contains particular undesirable organisms and to determine whether a pharmaceutical product conforms with a set standard for microbiological quality.
End-User (Food & Beverages, Pharmaceutical & Biotechnology, Agricultural, Environmental, Cosmetic and Personal Care)
The pharmaceutical & biotechnology segment is expected to account for 30% share of the global industrial microbiology testing services market by 2037. The second most popular test used by industrial microbiology to assess raw materials is microbial testing which is increasingly used by the pharmaceutical and biotechnology industries as they have specific needs, which are addressed by microbial solutions.
Besides this, the food & beverages segment is anticipated to gain significant share by the year 2037. The food sample's food additives, pollutants, and toxins are examples of food safety parameters to assure food quality and safety which are tested by microbial solutions.
Our in-depth analysis of the global industrial microbiology testing services market includes the following segments:
|
Test Type |
|
|
End-User |
|
|
Product Type |
|
North American Market Forecast
North America industry is estimated to dominate majority revenue share of 45% by 2037 impelled by the rising investment in the development of vaccines. This is expected to create a huge demand for industrial microbiology testing services in the region as it can be used to determine the quantity of microorganisms in a vaccination which often takes time since rigorous testing is necessary to make sure there are no unforeseen repercussions from them before distributing vaccines to the general public. For instance, for the development, manufacture, and acquisition of mRNA covid-19 vaccines, the US government spent more than USD 30 billion, before the pandemic until March 2022.
APAC Market Statistics
The APAC industrial microbiology testing services market is estimated to be the second largest, during the forecast timeframe led by the rising spending in healthcare. This has resulted in increasing spending research & development of reliable and efficient testing services to meet the rising need for quality control measures in the region. India spent over 1% of its GDP on healthcare in the year 2021.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?